INM

InMed Pharmaceuticals Inc

INM.US inmedpharma.com
1.31
+0.00 (+0.00%)
USD · NASDAQ
52-week range
0.58
2.50
Trading at 38% of the 52-week range
Market Cap
6.99M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
2.08
Div. Yield
N/A
% Institutions
84.66%
% Insiders
0.124%

1 Year

-39.6%

3 Year

-93.2%

10 Year

-99.9%
Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Company Information

Company Name
InMed Pharmaceuticals Inc
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: CA4576377002
CIK: 0001728328
CUSIP: 457637502
Currency: USD
Full Time Employees: 13
Phone: 604 669 7207
Fiscal Year End: June
IPO Date: Nov 12, 2020
Description:

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Address:

885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8

People

Directors & Officers

Name Title Year Born
Mr. Eric A. Adams B.S. Chem., M.I.B. President, CEO & Director 1964
Ms. N. Netta Jagpal CFO & Corporate Secretary 1973
Mr. Michael Woudenberg P.Eng. Chief Operating Officer 1970
Dr. Eric Chih-Hsien Hsu Ph.D. Senior Vice President of Preclinical Research & Development 1971
Dr. Sazzad Hossain M.Sc., Ph.D. Co-Founder 1958
Mr. Colin Clancy VP of Investor Relations & Corporate Communications NA
Mr. Jerry P. Griffin Vice President of Sales & Marketing NA
Dr. Shane A. Johnson Ph.D. Senior VP & GM of BayMedica NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 21, 2024 Andrew Hull N/A Purchase 1.88K $7.80 $14.63K
Feb 20, 2024 Eric A Adams N/A Purchase 2.08K $7.20 $14.98K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vivo Capital, LLC 798.38K Jun 30, 2026 14.95% $0.11 0.00%
Squadron Capital Management LLC 325.00K Jun 30, 2026 6.09% $0.16 0.00%
Sabby Management LLC 220.26K Mar 31, 2026 4.13% $0.32 9.24%
Citadel Advisors Llc 46.97K Mar 31, 2026 0.88% $0.00 0.00%
SEVEN GRAND MANAGERS, LLC 25.00K Jun 30, 2026 0.47% $0.00 0.00%
Virtu Financial LLC 19.98K Mar 31, 2026 0.37% $0.00 0.00%
TWO SIGMA SECURITIES, LLC 18.72K Mar 31, 2026 0.35% $0.00 0.00%
Stratos Wealth Partners, LTD 10.76K Jun 30, 2026 0.20% $0.00 0.00%
UBS Group AG 8.07K Mar 31, 2026 0.15% $0.00 2,040.05%
Private Wealth Management Group LLC 5.00K Jun 30, 2026 0.09% $0.00 0.00%
SBI Securities Co Ltd 300.00 Mar 31, 2026 0.01% $0.00 0.00%
Banque Cantonale Vaudoise 6.00 Mar 31, 2026 0.00% $0.00 0.00%
Federation des caisses Desjardins du Quebec 2.00 Mar 31, 2026 0.00% $0.00 0.00%
Susquehanna International Group, LLP 0.00 Mar 31, 2026 0.00% $0.00 -100.00%
Jane Street Group LLC 0.00 Mar 31, 2026 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 AdvisorShares Pure Cannabis ETF 16.43K 1.36% ▲ 0.00% Feb 26, 2025

Financial Highlights

Market Cap: $6.99M
EBITDA: $-7.83M
Book Value: $2.08
Earnings/Share: $-1.43
Profit Margin: -172.17%
Operating Margin: -162.75%
ROA (TTM): -54.61%
ROE (TTM): -112.65%
Revenue (TTM): $4.94M
Revenue/Share (TTM): $1.47
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -26.20%

Valuation Metrics

Enterprise Value: $2.36M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 5.34M
Shares Float: 831.86K
% Insiders: 0.124%
% Institutions: 84.66%
Short % Float: 1.36%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$3.18B
Cost of Goods Sold
adjust
$-2.47B
Gross Profit
subtotal
$709.84M
SG&A
adjust
$-1.88B
R&D
adjust
$-15.13M
Other Operating Expense
adjust
$-2.20M
Operating Income
subtotal
$-1.19B
Net Income
subtotal
$-1.19B

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about INM.US!